MingSight Buys Two Early-Stage Eye Drugs from Pfizer
October 12, 2010 at 10:52 AM EDT
MingSight Pharmaceuticals bought the worldwide rights to two Pfizer chemical entities, which MindSight will develop to treat ophthalmic diseases. Although MingSight is headquartered in San Diego, its R&D strategy involves collaboration with China partners. More details.... Stock Symbol: (NYSE: PFE)
